Recombinant human relaxin (rhRLX) modifies systemic arterial properties in conscious rats irrespective of gender, but in a biphasic fashion.
Chronic administration of recombinant human relaxin (rhRLX) to conscious female nonpregnant rats that reaches serum concentrations of 10-30 ng/mL increases cardiac output and reduces systemic arterial load comparable to levels observed in midterm pregnancy. Chronic administration of the hormone to male rats increases cardiac output and reduces systemic arterial load to a similar extent. Short-term or chronic administration of rhRLX to conscious female rats that reaches serum concentrations of approximately 80 ng/mL results in minimal and insignificant changes. We conclude that: (1) rhRLX increases cardiac output and reduces arterial load irrespective of gender, and (2)the rhRLX dose response is biphasic.
Debrah
Dan O
DO
Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Conrad
Kirk P
KP
Novak
Jackie
J
Danielson
Lee A
LA
Shroff
Sanjeev G
SG
D000818:Animals; D001794:Blood Pressure; D003331:Coronary Vessels / Q000187:drug effects*; D005260:Female; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D008297:Male; D051381:Rats; D011994:Recombinant Proteins / Q000494:pharmacology; D012065:Relaxin / Q000494:pharmacology*; D012727:Sex Characteristics
D011994:Recombinant Proteins; D012065:Relaxin